Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;22(3):225-235.
doi: 10.1007/s12012-021-09700-y. Epub 2021 Oct 20.

Exosomes: Potential Player in Endothelial Dysfunction in Cardiovascular Disease

Affiliations
Review

Exosomes: Potential Player in Endothelial Dysfunction in Cardiovascular Disease

Farahnaz Nikdoust et al. Cardiovasc Toxicol. 2022 Mar.

Abstract

Exosomes are spherical bilayer membrane vesicles with an average diameter of 40-100 nm. These particles perform a wide range of biological activities due to their contents, including proteins, nucleic acids, lipids, lncRNA, and miRNA. Exosomes are involved in inflammation induction, oxidative stress and apoptosis, which can be effective in endothelial dysfunction. Due to the induction of mentioned processes in the endothelial cells, the intercellular connections are destroyed, cell permeability increases and finally cell efficiency decreases and functional defects occur. Cardiovascular disease (CVDs) are of consequences of endothelial dysfunction. Thus by identifying the exosome signaling pathways, which induce inflammation, oxidative stress, and apoptosis, endothelial dysfunction and subsequently CVDs can be reduced; exosomes can be used for appropriate target therapy.

Keywords: Cardiovascular disease; Endothelial dysfunction; Exosome; Mechanism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Similar articles

Cited by

References

    1. Jokinen E. Obesity and cardiovascular disease. Minerva Pediatrica. 2014;67(1):25–32. - PubMed
    1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. Journal of the American Society of Nephrology: JASN. 1998;9(12 Suppl):S16–23. - PubMed
    1. Carter AM. Complement activation: An emerging player in the pathogenesis of cardiovascular disease. Scientifica. 2012 doi: 10.6064/2012/402783. - DOI - PMC - PubMed
    1. Farsad BF, Alavi SM, Ghorbanian G, Fahimi F, Ghaemmaghami Z, Mehr AZ, Bakhshandeh H. The therapeutic efficnecy of ranolazine in comparison with conventional therapy in diabetic individuals with ischemic heart disease; a randomized clinical trial. Journal of Renal Injury Prevention. 2019;9(1):e04–e04.
    1. Rahimi N. Defenders and challengers of endothelial barrier function. Frontiers in Immunology. 2017;8:1847. doi: 10.3389/fimmu.2017.01847. - DOI - PMC - PubMed

LinkOut - more resources